Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL.
Lanasa, MC; Davis, PH; Datto, M; Cook, H; Rizzieri, DA
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
51st Annual Meeting of the American-Society-of-Hematology
Conference Start Date
Conference End Date